Galapagos | GLPG - Current Assets


Galapagos reported EUR3.08B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
argenx SE USD 5.83B 946.64M Jun/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
Genmab DKK 2.88B 1.59B Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
GRIFOLS EUR 5.07B 274.77M Dec/2025
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
Merck EUR 13.23B 354M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sanofi EUR 30.95B 3.09B Dec/2025
UCB EUR 6.05B 733M Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025